Benzinga · Sep 15, 2026
Bionano Genomics Stock Surges Tuesday: What's Going On?
Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.
NYSE · BNGO
Bionano Genomics, Inc.
Healthcare · Medical - Diagnostics & Research
$1.73
Down-$0.01 (-0.57%)
Updated Sep 20, 2026, 11:36 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.48M
- P/E ratio
- -0.23
- Dividend yield
- 0.00%
- 52-week range
- $1.00 – $2.23
- Volume
- 1.2M
- Avg. volume
- 721.42K
Price performance
BNGO price history
1M range · 19 trading sessions · Daily adjusted prices
BNGO closed at $1.73 after 19 trading sessions, up 41.80% for the selected period.
- Last close
- $1.73
- Period change
- +41.80%
- Period low
- $1.17
- Period high
- $1.74
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $1.75 | $1.87 | $1.69 | $1.73 | 1.2M |
| Sep 17, 2026 | $1.53 | $1.855 | $1.50 | $1.74 | 2.5M |
| Sep 16, 2026 | $1.58 | $1.65 | $1.41 | $1.51 | 1.87M |
| Sep 15, 2026 | $1.31 | $2.23 | $1.31 | $1.56 | 39.78M |
| Sep 14, 2026 | $1.23 | $1.38 | $1.2143 | $1.33 | 409.55K |
| Sep 11, 2026 | $1.21 | $1.24 | $1.20 | $1.22 | 57.99K |
| Sep 10, 2026 | $1.18 | $1.24 | $1.16 | $1.20 | 288.14K |
| Sep 9, 2026 | $1.19 | $1.22 | $1.18 | $1.18 | 69.46K |
| Sep 8, 2026 | $1.21 | $1.2263 | $1.185 | $1.20 | 87.37K |
| Sep 4, 2026 | $1.25 | $1.25 | $1.195 | $1.20 | 177.45K |
| Sep 3, 2026 | $1.27 | $1.28 | $1.23 | $1.24 | 191.72K |
| Sep 2, 2026 | $1.22 | $1.28 | $1.2038 | $1.27 | 300.73K |
| Sep 1, 2026 | $1.21 | $1.22 | $1.17 | $1.22 | 208.66K |
| Aug 31, 2026 | $1.18 | $1.22 | $1.15 | $1.22 | 177.4K |
| Aug 28, 2026 | $1.23 | $1.24 | $1.16 | $1.17 | 179.63K |
| Aug 27, 2026 | $1.21 | $1.25 | $1.20 | $1.21 | 168.13K |
| Aug 26, 2026 | $1.24 | $1.26 | $1.205 | $1.21 | 157.09K |
| Aug 25, 2026 | $1.22 | $1.26 | $1.201 | $1.25 | 115.65K |
| Aug 24, 2026 | $1.22 | $1.25 | $1.18 | $1.22 | 133.38K |
Latest BNGO news
The latest Smart Investors Daily articles mentioning BNGO.
Stock researchCompany · Overview
BNGO research
Overview
Company profile and research snapshot.
Company profile
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $46.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 13, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 24, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 18, 2025 | HC Wainwright & Co. | Buy | — |
| May 20, 2025 | Maxim Group | Buy | — |
| Apr 9, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 14, 2026
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasmsSAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today highlighted three new independently authored
Benzinga · Sep 14, 2026
Bionano Genomics Highlights Three New Independently Authored, Peer-Reviewed Publications Showing Clinical Utility Of OGM In High-Risk Hematologic Malignancies
Bionano Genomics, Inc. (NASDAQ:BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk hematologic malignancies — myelodysplastic
Yahoo · Sep 10, 2026
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors (MACs), has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Vari
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
